Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV001022291 | SCV001184007 | pathogenic | Hereditary cancer-predisposing syndrome | 2023-08-24 | criteria provided, single submitter | clinical testing | The c.4321delG pathogenic mutation, located in coding exon 11 of the BRCA1 gene, results from a deletion of one nucleotide at nucleotide position 4321, causing a translational frameshift with a predicted alternate stop codon (p.D1441Tfs*15). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
| Labcorp Genetics |
RCV001380658 | SCV001578786 | pathogenic | Hereditary breast ovarian cancer syndrome | 2024-10-05 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asp1441Thrfs*15) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BRCA1-related conditions. ClinVar contains an entry for this variant (Variation ID: 824792). For these reasons, this variant has been classified as Pathogenic. |
| Baylor Genetics | RCV003473595 | SCV004211750 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2021-06-17 | criteria provided, single submitter | clinical testing |